article · Alimentary Pharmacology & Therapeutics

Clinical trial: An open‐label, randomised trial of different re‐start strategies after treatment withdrawal in HBeAg negative chronic hepatitis B

Asgeir Johannessen
Nina Weis
Signe Bollerup
Karin Lindahl
Nega Berhe
Dag Henrik Reikvam
Corina S. Rueegg
Anne‐Marte Bakken Kran
Marte Holmberg
Soo Aleman
Lars Heggelund
Tore Stenstad
Lars Normann Karlsen
Hans Erling Simonsen
Inge Christoffer Olsen
Anni Winckelmann
Ellen Samuelsen
Elisabeth Kleppa
Jan Svendsen
Pascal Brugger‐Synnes
Frank Olav Pettersen
Hailemichael Desalegn
Jonas Iversen
Olav Dalgård

202411 citationsOpen accessAddis Ababa University

Abstract

We could not confirm our hypothesis that a higher threshold for restart of therapy after NA withdrawal improves the likelihood of HBsAg loss within 36 months in patients with HBeAg negative CHB. Further studies including only patients with HBsAg level <1000 IU/mL and/or larger sample size and longer follow-up duration are recommended.

Research topics

Hepatitis B Virus Studies
Hepatitis C virus research
Liver Disease Diagnosis and Treatment

Sustainable Development Goals

3Good Health and Well-being

Read the original research

This page summarises published work. The authoritative version sits with the publisher.

View on publisher site Record on OpenAlex

DOI: 10.1111/apt.18147

Is something wrong with this record? Report it or request removal.

Discussion

Discuss this research

Have you built on this work, tried to replicate it, or seen it applied in practice? Share what you know. Verified researchers and MARATTO™ domain experts can open a discussion, and any member can reply. Contributions are reviewed before they appear.

No discussion yet. Open the first thread.

New to MARATTO™? Create a free account.